Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal dexmedetomidine, esketamine, or combination premedication in children undergoing tonsillectomy
ChiCTR2300076709Phase 4Not yet recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dexmedetomidine and esketamine in Emergence agitation (EA) (3 arms), sponsored by Fujian Provincial Hospital. Primary endpoint: Incidence of emergence delirium. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
dexmedetomidineesketamine
03
Conditions
Emergence agitation (EA)
Beyond the preview
Go deeper on ChiCTR2300076709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076709.